• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Mechanisms and prevention strategies of relapse and resistance after BCMA-CAR-T cell in multiple myeloma].

作者信息

Zhang L, Wang Y, Xu K L

机构信息

Blood Diseases Institute, Xuzhou Medical University; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University; Key Laboratory of Bone Marrow Stem Cell, Xuzhou 221002, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2021 Sep 14;42(9):778-781. doi: 10.3760/cma.j.issn.0253-2727.2021.09.014.

DOI:10.3760/cma.j.issn.0253-2727.2021.09.014
PMID:34753237
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8607042/
Abstract
摘要

相似文献

1
[Mechanisms and prevention strategies of relapse and resistance after BCMA-CAR-T cell in multiple myeloma].
Zhonghua Xue Ye Xue Za Zhi. 2021 Sep 14;42(9):778-781. doi: 10.3760/cma.j.issn.0253-2727.2021.09.014.
2
Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.BCMA 靶向 CAR-T 免疫疗法治疗多发性骨髓瘤和复发性/难治性多发性骨髓瘤概述。
Scand J Immunol. 2020 Aug;92(2):e12910. doi: 10.1111/sji.12910. Epub 2020 Jun 17.
3
[Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].[抗BCMA单次输注与抗CD19嵌合抗原受体T细胞联合输注用于复发/难治性多发性骨髓瘤免疫重建的比较]
Zhonghua Xue Ye Xue Za Zhi. 2021 Sep 14;42(9):733-738. doi: 10.3760/cma.j.issn.0253-2727.2021.09.004.
4
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原免疫疗法对多发性骨髓瘤具有广阔的应用前景。
Ann Hematol. 2019 Apr;98(4):813-822. doi: 10.1007/s00277-018-03592-9. Epub 2019 Jan 28.
5
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.经基因修饰表达抗 B 细胞成熟抗原嵌合抗原受体的 T 细胞可引起预后不良的复发性多发性骨髓瘤缓解。
J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29.
6
Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.APRIL 和基于抗体片段的骨髓瘤 CAR T 细胞均可通过 trogocytosis 和内化诱导 BCMA 下调。
J Immunother Cancer. 2022 Nov;10(11). doi: 10.1136/jitc-2022-005091.
7
[CAR-T therapy for multiple myeloma].[嵌合抗原受体T细胞疗法治疗多发性骨髓瘤]
Rinsho Ketsueki. 2023;64(11):1456-1464. doi: 10.11406/rinketsu.64.1456.
8
[Analysis of efficacy and safety of BCMA chimeric antigen receptor T cells in the treatment of 5 patients with recurrent/refractory IgD multiple myeloma].BCMA嵌合抗原受体T细胞治疗5例复发/难治性IgD型多发性骨髓瘤的疗效与安全性分析
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):1035-1037. doi: 10.3760/cma.j.issn.0253-2727.2023.12.012.
9
Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤患者接受成熟抗原（BCMA）嵌合抗原受体（CAR）-T细胞（HDS269B）治疗后的后续抗骨髓瘤治疗。
Am J Hematol. 2022 Dec;97(12):E478-E481. doi: 10.1002/ajh.26745. Epub 2022 Oct 17.
10
[CAR T-cell therapy for multiple myeloma].[嵌合抗原受体T细胞疗法治疗多发性骨髓瘤]
Internist (Berl). 2021 Jun;62(6):605-610. doi: 10.1007/s00108-021-01043-8. Epub 2021 May 3.

本文引用的文献

1
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.一名多发性骨髓瘤患者中，针对抗BCMA嵌合抗原受体T细胞的纯合BCMA基因缺失。
Nat Med. 2021 Apr;27(4):616-619. doi: 10.1038/s41591-021-01245-5. Epub 2021 Feb 22.
2
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.双等位基因 BCMA 缺失导致多发性骨髓瘤患者对 CAR T 细胞治疗产生耐药。
Nat Commun. 2021 Feb 8;12(1):868. doi: 10.1038/s41467-021-21177-5.
3
CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.基于 CRISPR 的筛选揭示了多发性骨髓瘤免疫治疗反应的决定因素。
Blood Adv. 2020 Jul 14;4(13):2899-2911. doi: 10.1182/bloodadvances.2019001346.
4
Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance.多发性骨髓瘤免疫治疗面临的挑战：骨髓微环境介导的免疫抑制和免疫抵抗
Cancers (Basel). 2020 Apr 17;12(4):988. doi: 10.3390/cancers12040988.
5
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.B 细胞成熟抗原（BCMA）在多发性骨髓瘤中的作用：靶向治疗的原理和当前的治疗方法。
Leukemia. 2020 Apr;34(4):985-1005. doi: 10.1038/s41375-020-0734-z. Epub 2020 Feb 13.
6
Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.抗 BCMA 嵌合抗原受体，具有完全人源重链单域抗原识别结构域。
Nat Commun. 2020 Jan 15;11(1):283. doi: 10.1038/s41467-019-14119-9.
7
B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.嵌合抗原受体 T 细胞治疗复发或难治性多发性骨髓瘤的 B 细胞成熟抗原特异性：一项荟萃分析。
Eur J Haematol. 2020 Apr;104(4):318-327. doi: 10.1111/ejh.13380. Epub 2020 Jan 20.
8
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.基于三聚体 APRIL 的 CAR 结合域的合理设计可实现多发性骨髓瘤的有效靶向。
Blood Adv. 2019 Nov 12;3(21):3248-3260. doi: 10.1182/bloodadvances.2019000703.
9
Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.嵌合抗原受体 T 细胞疗法的耐药机制及在 B 细胞血液恶性肿瘤中的克服策略。
Int J Mol Sci. 2019 Oct 10;20(20):5010. doi: 10.3390/ijms20205010.
10
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.γ-分泌酶抑制增强了 BCMA 特异性嵌合抗原受体 T 细胞在多发性骨髓瘤中的疗效。
Blood. 2019 Nov 7;134(19):1585-1597. doi: 10.1182/blood.2019000050.